A courageous six-year-old girl has regained her vision through groundbreaking eye gene therapy provided by the NHS. Saffie Sandford, residing in Stevenage, Hertfordshire, was diagnosed with Leber’s Congenital Amaurosis (LCA), a rare genetic eye condition that impairs normal vision due to a deficiency in specific eye proteins.
Individuals with LCA, especially infants and children, experience limited vision in daylight and total blindness in low-light conditions, with a risk of complete sight loss in adulthood. Saffie, a vibrant child fond of Spider-Man, started facing vision difficulties at the age of five, prompting her parents to seek medical help.
Following diagnostic tests at Moorfields Eye Hospital in London, Saffie underwent Luxturna eye gene therapy at Great Ormond Street Hospital. This pioneering treatment involves injecting a healthy gene copy directly into the eye, addressing the genetic root of LCA.
Saffie’s mother, Lisa, expressed gratitude for the NHS treatment, highlighting the significant impact it had on Saffie’s life. Before the therapy, Saffie’s condition severely limited her daily activities, particularly in low-light settings. However, following the treatment in both eyes, her vision dramatically improved, allowing her to engage in activities previously hindered by her condition.
Researchers from Great Ormond Street Hospital and University College London have conducted studies demonstrating the effectiveness of Luxturna in enhancing visual pathways in children with specific retinal diseases. While not a definitive cure, Luxturna shows promise in improving long-term sight outcomes, especially when administered during critical developmental stages.
Dr. Rob Henderson, an ophthalmologist at Great Ormond Street Hospital, emphasized the significant impact of gene therapy on children’s visual abilities and the importance of age-appropriate outcome assessments in future treatments. The research findings indicate a positive shift in the possibilities for children with inherited retinal diseases, setting new standards for gene therapy trials worldwide.